Exelixis (EXEL) Amortization of Deferred Charges (2014 - 2017)
Exelixis (EXEL) recorded quarterly Amortization of Deferred Charges of $12.0 million in Q4 2017, up 476.43% quarter-over-quarter from $2.1 million in Q2 2017, and up 96.26% on a YoY basis from $6.1 million in Q4 2016.
Exelixis (EXEL) Amortization of Deferred Charges (2014 - 2017) Analysis & Trends
Exelixis' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $12.0 million for Q4 2017.
- In Q4 2017, Amortization of Deferred Charges rose 96.26% year-over-year to $12.0 million; the TTM figure through Sep 2018 stood at $12.0 million (changed N/A YoY), while the FY2017 annual figure was $182000.0, down 97.73% from the prior year.
- Amortization of Deferred Charges was $12.0 million for Q4 2017 at Exelixis, up from $2.1 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $22.3 million in Q4 2014 to a low of $89000.0 in Q1 2017.
- Historically, Amortization of Deferred Charges has averaged $5.1 million across 4 years, with a median of $2.7 million in 2015.
- Biggest YoY gain for Amortization of Deferred Charges was 1743.36% in 2017; the steepest drop was 97.18% in 2017.
- A 4-year view of Amortization of Deferred Charges shows it stood at $22.3 million in 2014, then slumped by 86.86% to $2.9 million in 2015, then soared by 108.88% to $6.1 million in 2016, then surged by 96.26% to $12.0 million in 2017.
- The last three Amortization of Deferred Charges figures came in at $12.0 million (Q4 2017), $2.1 million (Q2 2017), and $89000.0 (Q1 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 29, 2017 | 12.01 Mn |
| Dec 29, 2017 | 12.01 Mn |
| Jun 30, 2017 | 2.08 Mn |
| Jun 30, 2017 | 2.08 Mn |
| Mar 31, 2017 | 89,000.00 |
| Mar 31, 2017 | 89,000.00 |
| Dec 30, 2016 | 6.12 Mn |
| Dec 30, 2016 | 6.12 Mn |
| Sep 30, 2016 | 121,000.00 |
| Sep 30, 2016 | 121,000.00 |
| Jun 30, 2016 | 113,000.00 |
| Jun 30, 2016 | 113,000.00 |
| Mar 31, 2016 | 3.16 Mn |
| Mar 31, 2016 | 3.16 Mn |
| Sep 30, 2015 | 2.93 Mn |
| Sep 30, 2015 | 2.93 Mn |
| Jun 30, 2015 | 2.37 Mn |
| Jun 30, 2015 | 2.37 Mn |
| Dec 31, 2014 | 22.29 Mn |
| Dec 31, 2014 | 22.29 Mn |